INDGN2024-04-012024-06-30 INDGN2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member INDGN2024-06-30 INDGN2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDGN2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544172 INDGN NOTLISTED Indegene Limited Equity 2024-04-01 2025-03-31 2024-08-01 2024-07-24 INR Millions First quarter 18:34:00 19:22:00 2024-08-01 2024-08-01 Not applicable Single segment Where financial results contain both consolidated financial results and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the consolidated financial results. 2024-04-01 2024-06-30 Unaudited Standalone 2586000000.00 137000000.00 2723000000.00 0.00 0.00 0.00 1853000000.00 15000000.00 66000000.00 338000000.00 2272000000.00 451000000.00 0.00 451000000.00 119000000.00 6000000.00 125000000.00 0.00 326000000.00 0.00 0.00 0.00 0.00 326000000.00 7000000.00 333000000.00 333000000.00 0.00 479000000.00 2 1.41 1.39 0.00 0.00 1.41 1.39 Notes to the Statement of Standalone Financial Results for quarter ended 30 June 2024 (All amounts in INR millions, except share data and where otherwise stated) 1. The above Standalone Financial Results of the Company have been prepared in accordance with Indian Accounting Standards ( Ind AS ) 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ( Ind AS ) prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ( the regulations ). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. ^ in the financial information denote amounts less than INR 0.50 million. 2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 01 August 2024. The statutory auditors have performed a limited review of the Standalone Financial Results for the quarter ended 30 June 2024 and have issued an unmodified review report on the same. 3. The Standalone Financial Results include the results for the quarter ended 31 March 2024 being the balancing figure between the audited figure in respect of the full financial year and the unaudited year to date figure up to 31 December 2023, which were subject to limited review. 4. The Standalone Financial Results for the quarter ended 30 June 2024, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations). 5. During the quarter ended 30 June 2024, the Company has completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of INR 2 each at an issue price of INR 452 per share, comprising fresh issue of 16,833,818 shares aggregating to INR 7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to INR 10,818. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company was not mandatorily required to prepare and publish quarterly results for the quarter ended 30 June 2023 in accordance with the regulations. 6. The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results. Other Expenses 338000000.00 The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results. Remeasurement of defined benefit obligation 15000000.00 15000000.00 4000000.00 Exchange differences on translating the financial statements of foreign operation -4000000.00 -4000000.00 0.00